American Society of Clinical Oncology
Public records show a registered, tax-exempt organization in good standing.
What it says it does
SEE SCHEDULE O:
- Income
- $159.1 million
- Spending
- $143.7 million
- Spent on programs
- 76%
- Reserves
- 12.2 months of spending
- Largest source of income
- fees for its services, 87%
- Employees
- 488
- Volunteers
- 5,127
- Highest pay
- $1.1 million, ceo
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Financial health
Good: 85 out of 100. Higher than 78% of charities in its peer group (diseases, over $100m).
Reserves
35 of 35Spendable reserves would cover 12.2 months of spending.
Debt
10 of 20It owes 35% of what it owns.
Living within its means
15 of 15Income exceeded spending by 10% of income.
Income trend
10 of 15Income fell 9% on the year before.
Spending floor
15 of 1576% of spending went to programs and raising each dollar of donations cost 0 cents.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Governance
Strong: 100 out of 100. Higher than 33% of charities in its peer group (diseases, over $100m).
Independent board
25 of 2518 of 18 voting board members are independent.
Conflict of interest policy
15 of 15Has a written conflict of interest policy.
Whistleblower policy
8 of 8Has a written whistleblower policy.
Record keeping policy
7 of 7Has a written policy on keeping and destroying records.
Board minutes
5 of 5Keeps minutes of board meetings.
Board sees the tax return
10 of 10Gave the board a copy of this return before filing it.
Pay set independently
5 of 5Sets its chief executive's pay through independent review and comparison.
Independent check of accounts
15 of 15Its accounts were audited by an independent accountant.
No reported misuse
10 of 10Reports no diversion of assets, excess benefits or loans to insiders.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Impact evidence
Describes programs. Its tax return describes what it does but we have found no measurable results in it.
Programs described in its return (4)
- $70.8 million spent. SEE SCHEDULE O:SCIENTIFIC & MEDICAL EDUCATION:ASCO'S MEETING PORTFOLIO DELIVERS, TO ASCO'S CORE AUDIENCE OF HEALTH PROFESSIONALS, THE SCIENCE AND EDUCATION CRITICAL TO IMPROVING PATIENT CARE AND CLINICAL PRACTICE BY HOSTING CONFERENCES THAT BRING TOGETHER FACULTY AND PRACTITIONERS BOTH IN-PERSON AND ONLINE. IN 2024, ASCO'S PREMIER ANNUAL MEETING, THROUGH OVER 200 SESSIONS, REACHED AN AUDIENCE OF 36,400 PROFESSIONALS, INCLUDING OVER 14,400 PROFESSIONALS FROM 140 NON-US COUNTRIES, BOTH IN-PERSON AND ONLINE. THROUGH ASCO'S ADDITIONAL MEETINGS, THE ASCO GASTROINTESTINAL CANCERS SYMPOSIUM, THE ASCO GENITOURINARY CANCERS SYMPOSIUM, THE ASCO QUALITY CARE SYMPOSIUM, ASCO BREAKTHROUGH, AND THE BEST OF ASCO MEETING, A FURTHER 10,400 PROFESSIONALS, OVER 4,100 OF WHOM WERE OUTSIDE THE UNITED STATES, BENEFITED FROM THE EDUCATION, SCIENCE, AND NETWORKING THAT ASCO PROVIDED.
- $9.4 million spent. SEE SCHEDULE O:RESEARCH INITIATIVES - TAPUR/CENTRA:ASCO'S CENTER FOR RESEARCH AND ANALYTICS "(CENTRA)" LEADS ASCO'S EFFORTS IN RESEARCH AND RELATED TO CLINICAL CANCER RESEARCH. MAJOR PROGRAMS AND PROJECTS INCLUDE: (1) THE TARGETED AGENT AND PROFILING UTILIZATION REGISTRY (TAPUR) STUDY, WHICH IS A PRECISION MEDICINE BASKET TRIAL THAT INVESTIGATES THE EFFICACY OF MORE THAN 15 DIFFERENT ANTI-CANCER TARGETED AGENTS IN PATIENTS WITH ADVANCED CANCERS AND HAS ENROLLED NEARLY 3,000 PATIENTS SINCE IT OPENED IN 2016. TAPUR CONTINUES TO PUBLISH TRIAL RESULTS IN PEER-REVIEWED CLINICAL CANCER RESEARCH JOURNALS AND PRESENT RESULTS AT CLINICAL CANCER RESEARCH CONFERENCES; (2) ASCO'S MEMBER RESEARCH SURVEY POOL, WHICH FACILITATES RESEARCH OF CANCER CARE PROVIDERS BY DISSEMINATING SURVEYS FROM MERITORIOUS SURVEY RESEARCH PROJECTS TO ASCO MEMBERS WHO HAVE AGREED TO BE A PART OF THE SURVEY POOL; (3) THE STATE OF CANCER CARE IN AMERICA PROGRAM, WHICH ASSESSES AND REPORTS ON THE STATE OF AND CHANGES IN CANCER CARE IN THE US; (4) ASCO'S WORK IN IMPROVING ACCESS TO CLINICAL TRIALS THROUGH TRAINING FOR SITES; AND (5) A PATIENT-CENTERED CLINICAL TRIAL, THE CDK4/6 INHIBITOR DOSING STUDY, WHICH OPENED TO ENROLLMENT IN DECEMBER 2024 AND EVALUATES STANDARD VS. TITRATED DOSING APPROACHES FOR PATIENTS AGE 65 AND OLDER WITH HR+/HER2- METASTATIC BREAST CANCER. CENTRA ALSO SUPPORTS WORKSHOPS, MEETINGS, AND RESEARCH PROJECTS WITH OTHER STAKEHOLDERS IN CANCER RESEARCH, INCLUDING THE NCI, THE FDA'S ONCOLOGY CENTER FOR EXCELLENCE, AND OTHER NON-PROFIT GROUPS, SUCH AS THE FRIENDS OF CANCER RESEARCH.
- $9.1 million spent. SEE SCHEDULE O:QUALITY OF CARE INITIATIVES:QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI) IS A QUALITY SELF-ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES. QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICES TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. PRACTICES PARTICIPATE ANNUALLY AND OVER 263 PRATICES PARTICAPTED IN 2024. QUALITY TRAINING PROGRAM. ASCO'S QUALITY TRAINING PROGRAM IS DESIGNED TO EDUCATE AND TRAIN HEMATOLGY-ONOCOLOGY PRACTICE TEAMS ON THE TECHNIQUES OF CLINICAL CARE AND OPERATIONAL PERFORMANCE QUALITY IMPROVEMENT. 290 ONCOLOGY PROFESSIONALS RECEIVED TRAINING IN 2024.GUIDELINES. ASCO'S GUIDELINES PROGRAM ENGAGES WITH MORE THAN 1,000 ASCO MEMBER VOLUNTEERS, ON A YEARLY BASIS, TO DEVELOP EXPERT RECOMMENDATIONS AND STANDARDS DESIGNED TO PROMOTE CONSISTENT, SAFE DELIVERY OF HIGH-QUALITY CANCER CARE WORLDWIDE. CLINICAL CONTENT IS DISSEMINATED USING PUBLISHED ARTICLES, RECOMMENDATION TABLES, ALGORITHMS, PODCASTS, VISUAL ABSTRACTS, AND OTHER RESOURCES ACCESSIBLE THROUGH ASCO JOURNALS, THE ASCO WEBSITE, AND THE ASCO GUIDELINES APP. GUIDELINES ARE AMONG THE MOST READ ARTICLES IN THE JOURNAL OF CLINICAL ONCOLOGY (JCO), WITH OVER 1.1 MILLION DOWNLOADS AND 503 CITATIONS IN 2024. ASCO PUBLISHES BETWEEN 25 AND 30 NEW OR UPDATED GUIDELINES EACH YEAR, WITH A GROWING LIBRARY OF GUIDELINE SUMMARIES THAT HAVE BEEN TRANSLATED INTO SPANISH. A TOTAL OF 39 GUIDELINE PRODUCTS WERE PUBLISHED IN THE JCO FAMILY OF JOURNALS IN 2024, INCLUDING SEVERAL RAPID RECOMMENDATIONS AND MULTIPLE ITERATIONS OF ASCO'S COMPREHENSIVE LIVING GUIDELINE THAT ADDRESSES THE CARE OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER.
- $20.3 million spent. POLICY:IN COLLABORATION WITH VOLUNTEER EXPERTS, ASCO WORKS TO ADDRESS A WIDE RANGE OF POLICY ISSUES THAT IMPACT THE CANCER CARE DELIVERY SYSTEM AND PEOPLE WITH CANCER. POLICY IS CONVEYED IN FORMAL STATEMENTS PUBLISHED IN ASCO JOURNALS, AND IN PUBLIC FACING COMMUNICATIONS CHANNELS. AREAS OF FOCUS INCLUDE QUALITY AND ACCESS TO CARE, INSURANCE ISSUES, COST, PREVENTION, SURVIVORSHIP, REIMBURSEMENT, AND SUPPORT FOR CLINICAL CANCER RESEARCH. IN 2024, ASCO CONTINUED TO DRAW PUBLIC ATTENTION TO THE PERSISTENT CRISIS OF DRUG SHORTAGES, THE ONGOING AND WORSENING HARMS RELATED TO AGGRESSIVE UTILIZATION MANAGEMENT PRACTICES, THE NEED TO SUSTAIN ACCESS TO EVIDENCE BASED CANCER CARE, THE NEED TO BALANCE BENEFITS/HARMS ASSOCIATED WITH USE OF ARTIFICIAL INTELLIGENCE IN CANCER CARE, AND THE IMPORTANCE OF TELEMEDICINE AS A COMPONENT OF HEALTH CARE DELIVERY.CENTER FOR GLOBAL IMPACT (CGI):ASCO'S INTERNATIONAL AFFAIRS DEPARTMENT HAS TRANSITIONED TO THE CENTER FOR GLOBAL IMPACT (CGI). CGI PARTNERS ACROSS ASCO AND ONCOLOGY COMMUNITIES WORLDWIDE TO INTEGRATE GLOBAL PERSPECTIVES INTO ASCO STRATEGIES AND OPERATIONS, AND TO CATALYZE AND ADVANCE ASCO'S GLOBAL IMPACT GOALS AS DIRECTED BY THE SOCIETY'S MISSION, VISION, AND STRATEGIC PLANS. CGI SERVES AS A RESOURCE ACROSS ASCO FOR GLOBAL ISSUES RELEVANT TO ASCO, WITH A PARTICULAR EMPHASIS ON VOLUNTEER ENGAGEMENT, DIPLOMACY, STRATEGIC PLANNING, PROGRAM DELIVERY, AND GLOBAL OPERATIONS. EXAMPLES OF OPERATIONS ARE AS FOLLOWS:- JOINT SESSIONS- INTERNATIONAL CANCER CORPS- INTERNATIONAL COURSES- INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD (IDEA)SCIENTIFIC PUBLICATIONS:ASCO PRODUCES A NUMBER OF PROFESSIONAL PUBLICATIONS AND GENERAL PUBLICATIONS FOCUSED ON CLINICAL ONCOLOGY. ASCO PUBLISHES HIGH-QUALITY, PEER-REVIEWED SCIENTIFIC PAPERS IN ITS JOURNALS: - JOURNAL OF CLINICAL ONCOLOGY (JCO)- JCO ONCOLOGY PRACTICE (JCO OP)- JCO GLOBAL ONCOLOGY (JCO GO)- JCO CLINICAL CANCER INFORMATICS (JCO CCI)- JCO PRECISION ONCOLOGY (JCO PO)- JCO ONCOLOGY ADVANCES (JCO OA)- ASCO DAILY NEWSASCO ALSO PROVIDES CONTENT AND DISTRIBUTION LISTS FOR TRADE PUBLICATIONS. WHILE NOT OWNED OR PUBLISHED BY ASCO, THE PUBLICATIONS COVER NEWS AND INFORMATION OF INTEREST TO THE PROFESSIONAL ONCOLOGY COMMUNITY.EDUCATION AND PROFESSIONAL DEVELOPMENT:IN 2024, ASCO LAUNCHED THE INAUGURAL LEADERSHIP DEVELOPMENT PROGRAM (LDP): LATIN AMERICA CLASS OF 12, CREATING A NETWORK OF PHYSICIAN LEADERS TO ADVANCE CANCER CARE. IN 2024, ASCO HAD RECORD VIRTUAL MENTORING PROGRAM PARTICIPATION (68% INCREASE), RESULTING IN THE CREATION OF A TECHNOLOGICAL SOLUTION TO MEET THE DEMAND. THE IN-TRAINING EXAM FOR ONCOLOGY FELLOWS HAD RECORD PARTICIPATION WITH 2333 TRAINEES FROM 20 COUNTRIES ACROSS THE GLOBE PARTICIPATING. ALL PROGRAMS SERVE THE PURPOSE OF BUILDING THE WORKFORCE.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Legitimacy checks
Is it registered with the IRS? Passed.
Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.
Has the IRS revoked its tax-exempt status? Passed.
Not on the IRS automatic revocation list.
Source: Automatic revocation of exemption list, Internal Revenue Service, file dated September 30, 2026.
Are donations tax-deductible? Passed.
On the IRS list of organizations eligible to receive tax-deductible contributions.
Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated September 10, 2026.
Is it keeping up with its IRS filings? Passed.
Most recent return on file covers the year ending December 2024.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.
How long has it been tax-exempt? Passed.
Recognized by the IRS since August 1965.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.
Is it in good standing with state regulators? Passed.
Not on California's list of charities barred from soliciting. Other states are not yet checked.
Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated October 7, 2026.
Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.